AMLX Amylyx Pharmaceuticals Inc

The three usd 100 stocks at steep discounts: 1. $AMLX - de-risked with high upside. The new cdc pbh reporting code will add more patients that were under general diabetes code benefit from the treatment. ALS success and this is even a 200 USD stock. 2. $CAPR - the fda approval of the UPL revised submission is just around the corner, actually any minute. odds of a crl letter are extremely low, and fda sending letter at this stage would look amateurish at best. downside limited. Senators lobbying and are on the case, pre mid term elections approval is ehat they need. 3 $CVM accelerated approval could be back on the cards and what this means is that drug can be sold while company collecting data from patients on the drug.

$AMLX Looking for a Moderna type move with AMLX ✌️ As soon as we start moving forward with commercialization, I think that’s exactly what we’re gonna see 😎 And then we still have additional pipelines  moving in a positive direction  

$AMLX new U.S. ICD-10-CM code for post-bariatric hypoglycemia (PBH)—the condition relevant to Amylyx's avexitide—then yes: it became effective today, October 1, 2026. The new code is E89.830 — Post bariatric hypoglycemia. It is part of the FY2027 ICD-10-CM code set, which applies to services from October 1, 2026 through September 30, 2027. CMS +2 That's significant for PBH because previously clinicians generally had to use broader hypoglycemia codes such as E16.1 (Other hypoglycemia) together with bariatric-surgery status. The CDC proposal specifically noted that this did not accurately identify PBH patients. Target 70 (with ALS and Wolfram target 100)

$AMLX This current situation is all wrong…. Were these institutions that own 95% of AMLX …are constantly lending out their shares to short. From the perspective of a long shareholder, it’s completely backwards: …”If you’re invested alongside me because you believe the shares have value, why are you collecting a lending fee to provide ammunition to somebody betting on the opposite outcome?” And even when AMLX gets constructive analyst commentary this morning, …including a $45 Stifel target …..we STILL see a constant sell off. AMLX is doing great …..and none of this downtrend is related to the company operations…… it’s directly related to the very institutions that claim they’re backing the company.

$AMLX the beauty with random short selleras is THEY ALL START RACING to COVER! 14 mln shares short in a drug that is orphan, breakthru, and... Acquistion target!. adding at each drop!. target 72 (100+ with ALS)

$AMLX For the love of God, would y’all please stop shorting this company…. They now have life-changing products …and all you “shorts” just wanna beat it down . And that goes directly to all you institutional investors here ….as you keep lending your shares out to short …shame on every one of you ..😡 I hope ALL “shorts” get burned here very soon 

$AMLX three wave corrective-looking pullback may be complete with break out of falling wedge

$AMLX Conservative revenue of 3 Billion. Conservative multiple of 3. 10 Billion market cap here soon.